Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Price Regulator Wants At Least Five Drug Makers Charged

This article was originally published in PharmAsia News

Executive Summary

India's regulator of drug prices has called for legal action against five pharmaceutical companies on charges they violated price controls. The National Pharmaceutical Pricing Authority said the companies collectively sold 39 specified pack sizes of different drugs without prior approval of the prices. The firms named were Alembic, Cadilla Healthcare, Medley Pharmaceuticals, Lupin and Wockhardt. The NPPA said it also is looking at nearly 30 other cases of alleged overcharges and is asking the firms involved to repay the excess amounts. It asked state governments to begin prosecution proceedings. (Click here for more

You may also be interested in...

Drug Safety Panel Urges New Entity To Oversee Japan Drug Approvals

TOKYO - An ad hoc study commission debating prevention of recurring drug-induced hepatitis and HIV infections has recommended creating an independent entity that would supervise pharmaceutical approvals, drug safety and adverse events in an effort to toughen Japanese new drug approval processes

Drug Safety Panel Urges New Entity To Oversee Japan Drug Approvals

The independent, neutral body would be charged with monitoring, inspecting and investigating MHLW, the Pharmaceutical and Medical Devices Agency and other government administrative functions.

Mitsubishi Tanabe Reports ¥9.1 Billion In Losses From Hep C Suits

TOKYO - Osaka, Japan-based Mitsubishi Tanabe Pharma reported May 7 ¥9.1 billion ($87.5 million) in special losses for fiscal 2007 due to pending damages suits over its tainted blood products that caused hepatitis C. The company, which was established in October 2007 through a merger between Tanabe Seiyaku Co. and Mitsubishi Pharma, said the sum has been set aside as a provision for possible payments to settle such suits. Mitsubishi Pharma was the successor to defunct blood products maker Green Cross Corp., which sold the virus-tainted blood products, Japanese Kyodo News Agency said in a report




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts